ClinicalTrials.gg
Not yet recruitingNCT07767448Updated Nov 18, 2026

Skin Changes From the Use of Moisturizers in Participants With Cancer Experiencing Dermatological Adverse Events

An interventional study of CeraVe Moisturizing Cream and La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream in Cancer, sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Stanford University · Not applicable, Interventional, and Supportive care

Updated Nov 18, 2026Start date movedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate whether cosmeceutical topical moisturizers can help with skin dryness in participants with cancer experiencing a dermatological adverse event from cancer therapies. The main question it aims to answer is:

Does cosmeceutical topical moisturizers help with skin dryness?

Participants will:

  • Visit the clinic for a baseline visit to complete skin evaluation and tests.
  • Apply cosmeceutical topical moisturizers daily from baseline up until the follow-up visit.
  • Visit the clinic for a follow-up visit (approximately 2-4 weeks from baseline) for a repeat skin evaluation and tests.
02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's planned enrollment of 50 is below the median of 60 across 7,712 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Stanford University is the lead sponsor of 2,173 studies on the registry; 433 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient (18 years or older).
  • Patients diagnosed with cancer.
  • Patient receiving cancer treatment or therapy (receiving chemotherapy, targeted treatment, hormonal therapy, and/or ).
  • Patient experiencing a dermatological adverse event reporting dry skin from a cancer treatment or therapy.

Exclusion criteria

Exclusion Criteria:

  • Patient is unable to understand scope of the study.
  • Patient is unable to provide written .
  • Patient is healthy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Moisturizer

    Participants in this arm will apply the following cosmeceutical topical moisturizers twice daily (once in the morning and once in the evening) for the duration of the study: 1. CeraVe Moisturizing Cream (once in the morning and once in the evening) 2. La Roche Posay Lipikar AP+ triple repair moisturizing cream (once in the morning and once in the evening) 3. La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+) (once in the morning and once in the evening)

    Other: CeraVe Moisturizing Cream · Other: La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream · Other: La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+)

Interventions

  • OtherCeraVe Moisturizing Cream

    Moisturizer applied once in the morning and once in the evening.

  • OtherLa Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream

    Moisturizer applied once in the morning and once in the evening.

  • OtherLa Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+)

    Balm applied once in the morning and once in the evening.

06

What researchers measure

Primary outcomes

  1. Change in Patient-Reported Skin Dryness Severity

    Change in patient-reported skin dryness severity from baseline to follow-up visit (2-4 weeks) as measured by validated dryness severity scale (0-10 numerical rating scale where 0 = no dryness and 10 = severe dryness).

    Time frame: From baseline visit to follow-up visit (approximately 2-4 weeks).

Secondary outcomes

  1. Time to improvement in dryness symptoms

    The time from baseline to the first documented improvement in dryness symptoms, defined as either a ≥2-point reduction in dryness severity score from baseline or patient-reported meaningful improvement in dryness symptoms, whichever occurs first. Lower values indicate a faster improvement in symptoms.

    Time frame: From baseline visit to follow-up visit (2-4 weeks).

  2. Change in Stratum Corneum Hydration

    Change in skin hydration from baseline to follow-up, measured using corneometry and reported in corneometry units (CU). Higher corneometry values indicate greater stratum corneum hydration. Positive changes from baseline reflect improved skin hydration, whereas negative changes indicate reduced hydration.

    Time frame: From baseline visit to follow-up visit (2-4 weeks).

  3. Change in Transepidermal Water Loss (TEWL)

    Change in skin barrier function from baseline to follow-up, measured by transepidermal water loss (TEWL) and reported in g/h/m². TEWL quantifies the amount of water that passively evaporates through the skin. Lower TEWL values indicate improved skin barrier integrity and reduced water loss, while higher values indicate increased barrier disruption. Negative changes from baseline reflect improvement, whereas positive changes indicate worsening skin barrier function.

    Time frame: From baseline visit to follow-up visit (2-4 weeks).

07

Study locations

1 site
  • Stanford Health Care: Supportive Dermato-Oncology Program
    Palo Alto, California 94304, United States
    • Hannah Clinical Research Coordinator · Contacthannah05@stanford.edu · 650-487-1218
    • Lisa Zaba, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Sep 2028, 22 months later.

Of 1,988 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 22 months is below that.

Counting every sponsor, half of 2,063 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2026
First posted
Aug 17, 2026
StartEst.
Nov 2026was Oct 2026
Primary completionEst.
Sep 2028
CompletionEst.
Feb 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Nov 2026
Nov 18, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedPatient experiencing a dermatological adverse event reporting dry skin from a cancer treatment or therapy.
Nov 18, 2026
Interventions
Added CeraVe Moisturizing Cream; removed La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body Wash
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Oct 2026→Nov 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatient experiencing a dermatological adverse event reporting dry skin from a cancer treatment or therapy.
    Interventions Added CeraVe Moisturizing Cream; removed La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body Wash
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07767448
Collaborators
L'Oreal
Responsible party
Sponsor
First posted
Aug 17, 2026
Start date
Nov 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Clinical Research Coordinator
Contact
hannah05@stanford.edu
650-497-1218
Lisa Zaba, MD, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion